Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sham Mailankody

Showing results (91-100 of 174) with videos related to

Pageof 18
Sort By:
Leukemia & Lymphoma|May 10, 2017
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenanceHani Hassoun, Mikhail Roshal, Joshua Sabari, et al.
Clinical Biochemistry|September 25, 2016
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral bloodKazunori Murata, Samuel I McCash, Brittany Carroll, et al.
Blood|March 30, 2016
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myelomaNikoletta Lendvai, Andrew J Yee, Ioanna Tsakos, et al.
Leukemia & Lymphoma|June 1, 2022
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approachOscar B Lahoud, Heather Landau, James Nguyen, et al.
Plos One|November 2, 2018
Dietary intake is associated with risk of multiple myeloma and its precursor diseaseMarianna Thordardottir, Ebba K Lindqvist, Sigrun H Lund, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
JAMA Network Open|March 22, 2022
Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial ParticipationAngela K Green, Sara M Tabatabai, Xing Bai, et al.
Nature Medicine|January 23, 2023
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Jeffrey V Matous, Saurabh Chhabra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2024
Quality of Treatment Selection for Medicare Beneficiaries With CancerAaron P Mitchell, Sonia Persaud, Akriti Mishra Meza, et al.
Nature Medicine|March 18, 2023
Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Jeffrey V Matous, Saurabh Chhabra, et al.
Pageof 18

Showing results (91-100 of 174) with videos related to

Sort By:
Pageof 18
Leukemia & Lymphoma|May 10, 2017
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenanceHani Hassoun, Mikhail Roshal, Joshua Sabari, et al.
Clinical Biochemistry|September 25, 2016
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral bloodKazunori Murata, Samuel I McCash, Brittany Carroll, et al.
Blood|March 30, 2016
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myelomaNikoletta Lendvai, Andrew J Yee, Ioanna Tsakos, et al.
Leukemia & Lymphoma|June 1, 2022
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approachOscar B Lahoud, Heather Landau, James Nguyen, et al.
Plos One|November 2, 2018
Dietary intake is associated with risk of multiple myeloma and its precursor diseaseMarianna Thordardottir, Ebba K Lindqvist, Sigrun H Lund, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
JAMA Network Open|March 22, 2022
Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial ParticipationAngela K Green, Sara M Tabatabai, Xing Bai, et al.
Nature Medicine|January 23, 2023
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Jeffrey V Matous, Saurabh Chhabra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2024
Quality of Treatment Selection for Medicare Beneficiaries With CancerAaron P Mitchell, Sonia Persaud, Akriti Mishra Meza, et al.
Nature Medicine|March 18, 2023
Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Jeffrey V Matous, Saurabh Chhabra, et al.
Pageof 18